Hyderabad, Telangana, India, October 2025 — MSN Laboratories has announced the appointment of Kalakuntla Srinivas Rao as Executive Vice President – Formulations, marking a key leadership addition to its formulations manufacturing division. With over two decades of experience in the pharmaceutical industry, Srinivas brings proven expertise in formulation development, large-scale manufacturing, and operational excellence.
In his new role, he will lead MSN Laboratories’ formulations manufacturing vertical, focusing on driving innovation, quality systems, compliance, and efficiency across the company’s global operations. His appointment underscores MSN Laboratories’ commitment to strengthening its leadership team as it continues to expand its presence in the global formulations market.
Before joining MSN Laboratories, Srinivas spent more than nine years at Lupin, where he advanced from Senior General Manager to Senior Vice President, overseeing pharmaceutical manufacturing as Cluster Head. During his tenure, he was instrumental in optimizing large-scale production processes, strengthening regulatory compliance, and driving operational excellence across multiple manufacturing sites.
Earlier, he served as Director at Novast Laboratories Ltd. in China, where he contributed to the company’s global manufacturing operations and compliance initiatives, ensuring adherence to stringent international quality standards.
Srinivas began his career with Dr. Reddy’s Laboratories, where he spent nearly 15 years progressing from Trainee to Associate Director. His long tenure at Dr. Reddy’s helped him build a strong foundation in formulation technology, manufacturing systems, and organizational development, contributing to the company’s growth and global recognition.
At MSN Laboratories, Srinivas Rao’s strategic vision and deep domain expertise are expected to play a pivotal role in advancing the company’s innovation pipeline and reinforcing its leadership in the formulations space.
About MSN Laboratories
MSN Group is a research-driven, fully integrated global pharmaceutical company headquartered in Hyderabad, India, founded in 2003 with the mission to make high-quality medicines affordable and accessible worldwide. The organization operates 25 state-of-the-art manufacturing facilities (17 API and 8 Finished Dosage Facilities) across India and the USA.
With a robust R&D centre integrating API and Finished Dosage research under one roof, MSN rapidly introduces new and affordable therapies to global markets. Supported by a team of over 15,000 qualified professionals, MSN Group has built a strong global reputation for innovation, quality, and speed of delivery across its product portfolio.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work
